The NQO1 C609T polymorphism is associated with risk of secondary malignant neoplasms after treatment for childhood acute lymphoblastic leukemia: a matched-pair analysis from the ALL-BFM study group.
In a matched-pair study, we analyzed the association of a phenotypically relevant NQO1 polymorphism (C609T) with risk of secondary malignant neoplasms (SMN) after treatment for childhood acute lymphoblastic leukemia. Patients carrying a variant low-activity NQO1 allele had a significantly increased risk of developing a SMN. The observed effect was restricted to solid tumors.
Stanulla
Martin
M
Dynybil
Christian
C
Bartels
Dorothee B
DB
Dördelmann
Michael
M
Löning
Lutz
L
Claviez
Alexander
A
Schrappe
Martin
M
D000971:Antineoplastic Combined Chemotherapy Protocols; D001215:Asparaginase; D002648:Child; D002675:Child, Preschool; D003630:Daunorubicin; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D016555:Matched-Pair Analysis; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000235:genetics*; D016609:Neoplasms, Second Primary / Q000235:genetics*; D011110:Polymorphism, Genetic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy; D011241:Prednisone; D014750:Vincristine
D014750:Vincristine; D016660:NAD(P)H Dehydrogenase (Quinone); C447479:NQO1 protein, human; D001215:Asparaginase; D011241:Prednisone; D003630:Daunorubicin